Sign In
Buy PTN
$11.77
+0.0500 (+0.427%)
At Close: Jun 22, 2026
Palatin Announces 1-for-50 Reverse Stock Split
04:00pm, Friday, 08'th Aug 2025
PRINCETON, N.J. , Aug. 8, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTCQB: PTNT), today announced a reverse stock split ("Reverse Stock Split") of its shares at a ratio of 1-for-50.
Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity
07:30am, Tuesday, 15'th Jul 2025
Oral PL7737 monotherapy produced rapid and significant weight loss after just 4 days of treatment Combination of oral PL7737 and tirzepatide resulted in additive weight loss effects IND-enabling toxic
Palatin Technologies, Inc. (PTN) Q3 2025 Earnings Call Transcript
06:43pm, Thursday, 15'th May 2025
Palatin Technologies, Inc. (PTN) Q3 2025 - Earnings Conference Call May 14, 2025 11:00 AM ET Company Participants Carl Spana - CEO and President Stephen Wills - CFO, COO, Treasurer and Secretary Confe
Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025
07:30am, Friday, 09'th May 2025
Findings highlight PL9654 and PL9655's potential to treat diabetic retinopathy through inflammation resolution, vascular stabilization, and neuroprotection PL9654 and PL9655 down-regulate inflammatory
Palatin Technologies Announces Closing of Reduced Public Offering
10:19pm, Thursday, 08'th May 2025
Company Transitioned onto the OTC Pink CRANBURY, N.J. , May 8, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTC PINK: PTNT) ("Palatin" or the "Company"), a biopharmaceutical company developing fir
NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN)
05:20pm, Wednesday, 07'th May 2025
NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common s
Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice
08:15am, Wednesday, 07'th May 2025
Funding Supports Advancement of Obesity Program and Strategic Business Development Initiatives Advancement of novel next-generation MC4R long-acting peptides and oral small molecules IND applications
Palatin Technologies Announces Pricing of up to $23 Million Public Offering
08:00am, Wednesday, 07'th May 2025
$11.5 Million Upfront with up to an Additional $11.5 Million Upon the Cash Exercise of the Milestone Related Warrants CRANBURY, N.J. , May 7, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amer
Topical melanocortin therapy shows promise for treating glaucoma PL9588 lowers intraocular pressure (IOP) by increasing aqueous outflow Demonstrates neuroprotection independent of IOP reduction Suppor
Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease
07:30am, Tuesday, 29'th Apr 2025
Updated Phase 3 analyses position PL9643 as a potential first-in-class therapy achieving full symptom resolution in dry eye disease. Responder analyses demonstrated statistically significant symptom c
Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide
07:30am, Thursday, 17'th Apr 2025
Co-administered bremelanotide + tirzepatide, bremelanotide alone, and tirzepatide alone arms showed improvement in appetite suppression, fullness, and satiety Bremelanotide matched or exceeded tirzepa
Palatin Appeals NYSE American Notice of Delisting
07:00am, Monday, 14'th Apr 2025
Company working aggressively to regain compliance Common stock to continue to trade on NYSE American during the appeal process CRANBURY, N.J. , April 14, 2025 /PRNewswire/ -- Palatin Technologies, In
NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN)
04:15pm, Thursday, 10'th Apr 2025
NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common s
Six-month open-label study showed clinically meaningful improvements in kidney function and disease in patients with Type 2 diabetic nephropathy. 71% achieved a >30% reduction in UP/Cr, a key indicato
Primary endpoint met in the 8-week treatment study (highly statistically significant). Co-administered group had a 4.4% reduction in weight compared to 1.6% for the placebo group (p
